Details for Patent: 10,752,634
✉ Email this page to a colleague
Which drugs does patent 10,752,634 protect, and when does it expire?
Patent 10,752,634 protects IMBRUVICA and is included in two NDAs.
Protection for IMBRUVICA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eighty-two patent family members in thirty-one countries.
Summary for Patent: 10,752,634
| Title: | Crystalline forms of a brutons tyrosine kinase inhibitor |
| Abstract: | Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. |
| Inventor(s): | Purro; Norbert (Los Gatos, CA), Smyth; Mark S. (Granite Bay, CA), Goldman; Erick (Concord, CA), Wirth; David D. (Oak Ridge, NC) |
| Assignee: | Pharmacyclics LLC (Sunnyvale, CA) |
| Application Number: | 16/837,665 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Dosage form; |
Drugs Protected by US Patent 10,752,634
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,752,634
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 092844 | ⤷ Sign Up | |||
| Argentina | 118108 | ⤷ Sign Up | |||
| Australia | 2013271918 | ⤷ Sign Up | |||
| Australia | 2016250445 | ⤷ Sign Up | |||
| Australia | 2018211201 | ⤷ Sign Up | |||
| Australia | 2018211216 | ⤷ Sign Up | |||
| Australia | 2020239751 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
